Isomab is a UK-based biopharmaceutical company developing first-in-class antibody therapies to treat cardiovascular and peripheral ischemic diseases.
Isomab’s research is built on more than 20 years of work studying the balance between two Vascular Endothelial Growth Factor (VEGF-A) isoforms, namely VEGF-A165a and VEGF-A165b.
Spun out of the University of Nottingham in 2022, its technology focuses on blocking specific VEGF-A isoforms to stimulate the growth of new blood vessels and restore healthy blood flow.
Partnerships, investment, and scientific collaboration enquiries welcome.